The sensors, manufactured and sold by DexCom, a San Diego-based diabetes care company, have received FDA approval for OTC use. Abbott Laboratories, another key player in the market, is set to release its own system in the summer of 2024, although pricing details have not yet been disclosed.
Experts estimate the market for these products could encompass up to 100,000 people, including prediabetic individuals and those with diabetes who do not use insulin.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
